Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000044

Drug Information
NameDutasteride
SynonymsAC1L49EM; NSC740477; Dutasteride; GG-745; FT-0080365; GI-198745; C27H30F6N2O2; CHEMBL283245; DB01126; Avolve; CID9914880; Avodart; GI 198745; AC1OCF98; MolPort-003-847-041; CID152945; GI-198745X; N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; 1H-Indeno(5,4-f)quinoline-7-carboxamide, N-(2,5-bis(trifluoromethyl)phenyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-; Duagen; CHEBI:132773; alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide; Dutasteride [USAN]; 164656-23-9; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; Avodart (TN); Bio-0167; Dutasteride (JAN/USAN/INN); Avodart, Dutasteride; D03820; (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; GG 745; MolPort-003-666-660; S1202_Selleck; (1S,3aS,3bS,5aR,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (5.alpha.,17.beta.)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride;Avodart;; CID6918296; LS-173584; ZINC03932831; UNII-O0J6XJN02I; CHEMBL1200969
Trade NameAvodart; Avidart; Avolve; Duagen; Dutas; Dutagen; Duprost
CompanyGSK
IndicationBenign prostatic hyperplasia
[ICD9: 600   ICD10: N40]
Approved    [1]
Prostate cancer
[ICD9: 185   ICD10: C61]
Phase III    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21
)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32
)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36
)/t15-,16-,17-,19+,21+,24-,25+/m0/s1
InChIKeyJWJOTENAMICLJG-QWBYCMEYSA-N
Canonical SMILESCC12CCC3C(C1CCC2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CCC5C3(C=CC(=O)N5)
C    
Isomeric SMILESC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)
(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C
Therapeutic ClassAntihyperplasia Agents
Antineoplastic Agents
CAS NumberCAS 164656-23-9
FormulaC27H30F6N2O2
PubChem Compound IDCID 6918296.
PubChem Substance IDSID 12014955.
SuperDrug ATC IDG04CB02
SuperDrug CAS ID164656239;
Target5-alpha reductaseInhibitor[2]
5-alpha reductaseInhibitor[3]
Ref 15alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):389-402. To Reference
Ref 2GSK. Product Development Pipeline. February 2009. To Reference
Ref 3The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543